CIK 0000879407 · Large accelerated filer
ARROWHEAD PHARMACEUTICALS, INC.
Sign in to watch- Ticker
- ARWR
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Sep 30
- Incorporated
- DE
- Entity type
- operating
- EIN
- 460408024
- Phone
- 626-696-4702
- Business address
- 177 E COLORADO BLVD, SUITE 700, PASADENA, CA, 91105
- Former names
- ARROWHEAD RESEARCH CORP, INTERACTIVE GROUP INC, INTERACTIVE INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $1,186,600
- in 2 filings
Net −$1,186,600. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-12-31 | O'Brien Patrick COO | Gift 10b5-1 | −560 | 525,521 | ||
| 2025-12-31 | O'Brien Patrick COO | Gift 10b5-1 | −560 | 524,961 | ||
| 2025-12-31 | O'Brien Patrick COO | Gift 10b5-1 | −560 | 524,401 | ||
| 2025-12-29 | Anzalone Christopher Richard Chief Executive Officer | Option exercise 10b5-1 | +35,181 | $6.15 | $216K | 3,841,107 |
| 2025-12-29 | Anzalone Christopher Richard Chief Executive Officer | Option exercise 10b5-1 | +16,545 | $6.15 | $102K | 3,857,652 |
| 2025-12-29 | Anzalone Christopher Richard Chief Executive Officer | Sale 10b5-1 | −35,181 | $69.33 | $2.4M | 3,822,471 |
| 2025-12-29 | Anzalone Christopher Richard Chief Executive Officer | Sale 10b5-1 | −16,545 | $68.69 | $1.1M | 3,805,926 |
| 2025-12-29 | Anzalone Christopher Richard Chief Executive Officer | Option exercise · Stock Option (right to buy Common Stock) 10b5-1 | −35,181 | 16,545 | ||
| 2025-12-29 | Anzalone Christopher Richard Chief Executive Officer | Option exercise · Stock Option (right to buy Common Stock) 10b5-1 | −16,545 | 0 | ||
| 2025-12-26 | Ferrari Mauro Director | Sale 10b5-1 | −7,530 | $70.00 | $527K | 69,053 |
| 2025-12-22 | Anzalone Christopher Richard Chief Executive Officer | Sale 10b5-1 | −10,012 | $68.33 | $684K | 3,808,500 |
| 2025-12-22 | Anzalone Christopher Richard Chief Executive Officer | Sale 10b5-1 | −2,574 | $68.85 | $177K | 3,805,926 |
| 2025-12-19 | Vakiener Victoria Director | Sale 10b5-1 | −2,799 | $66.63 | $186K | 42,964 |
| 2025-12-19 | Vakiener Victoria Director | Sale 10b5-1 | −5,281 | $67.97 | $359K | 37,683 |
| 2025-12-19 | Vakiener Victoria Director | Sale 10b5-1 | −1,960 | $68.39 | $134K | 35,723 |
| 2025-12-19 | Waddill William D. Director | Sale 10b5-1 | −2,416 | $66.66 | $161K | 62,514 |
| 2025-12-19 | Waddill William D. Director | Sale 10b5-1 | −5,451 | $68.01 | $371K | 57,063 |
| 2025-12-19 | Waddill William D. Director | Sale 10b5-1 | −500 | $68.53 | $34K | 56,563 |
| 2025-12-19 | Anzalone Christopher Richard Chief Executive Officer | Sale 10b5-1 | −3,979 | $66.67 | $265K | 3,827,978 |
| 2025-12-19 | Anzalone Christopher Richard Chief Executive Officer | Sale 10b5-1 | −8,147 | $68.01 | $554K | 3,819,831 |
Page 3 of 28 · 542 trades